Novo Nordisk has said that it has got Indian regulatory approval for its weight-loss medication, Wegovy. This is a major step towards controlling the rising levels of obesity in the country, especially in women. Wegovy, a weekly injection, has proven to enable users to lose around 15% of their body weight. With the Indian market set to experience high demand, Novo Nordisk is planning to bring the drug to market by 2026, though it will have competition from domestic generic players working on their own versions. The company is determined to make enough supply available to cover expected demand.
Source: Economic Times, Business Standard, Reuters.